record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundobservational · manual state transition · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
species
Homo sapiens
evidence spans
FDA accelerated approval of aducanumab (Aduhelm) June 2021 was contested at the FDA Advisory Committee (10-0 vote against, plus 1 uncertain); the surrogate-endpoint approval mechanism was used over Advisory Committee opinion. Three FDA AC members resigned in protest.
Cascade-densification deposit: Aducanumab Phase Ib (Sevigny 2016) → ENGAGE/EMERGE controversy + scope flags · curator_source · Cascade-densification deposit: Aducanumab Phase Ib (Sevigny 2016) → ENGAGE/EMERGE controversy + scope flags
conditions
Provenance
source title
Cascade-densification deposit: Aducanumab Phase Ib (Sevigny 2016) → ENGAGE/EMERGE controversy + scope flags
authors
reviewer:will-blair-bot
FDA accelerated approval of aducanumab (Aduhelm) June 2021 was contested at the FDA Advisory Committee (10-0 vote against, plus 1 uncertain); the surrogate-endpoint approval mechanism was used over Advisory Committee opinion. Three FDA AC members resigned in protest.
vs_8da6a2f531df04ff · source:Cascade-densification deposit: Aducanumab Phase Ib (Sevigny 2016) → ENGAGE/EMERGE controversy + scope flags|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_a0c1a74912e3681cfinding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_f039c561f98f9930finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_0b31053ba6f0303dfinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_3fcd40e83d26271cfinding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.